Jeremy Bender Sells 16,058 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 16,058 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.77, for a total value of $108,712.66. Following the sale, the chief executive officer owned 161,365 shares of the company’s stock, valued at approximately $1,092,441.05. This represents a 9.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Trading Down 0.1%

Day One Biopharmaceuticals stock opened at $6.81 on Thursday. The stock has a market cap of $697.55 million, a PE ratio of -7.17 and a beta of -1.26. The stock has a 50-day moving average price of $6.61 and a 200 day moving average price of $7.71. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $33.91 million during the quarter, compared to analysts’ expectations of $35.55 million. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%. On average, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors have recently modified their holdings of DAWN. GF Fund Management CO. LTD. purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $27,000. Ameritas Investment Partners Inc. grew its holdings in shares of Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the period. Entropy Technologies LP purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $67,000. Prudential Financial Inc. purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $69,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $76,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analyst Ratings Changes

DAWN has been the subject of several recent analyst reports. Needham & Company LLC lowered their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Piper Sandler initiated coverage on Day One Biopharmaceuticals in a report on Monday. They issued an “overweight” rating and a $25.00 price target for the company. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.